This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-Researchers and Healthcare Providers
 Research Grants Program
-Medical and Scientific Advisory Council
 Recent Recommendations
 What is MASAC?
 All MASAC Recommendations
 MASAC Members
 Nursing Working Group
 Social Work Working Group
 Physical Therapy Working Group
 Comprehensive Medical Care - Hemophilia Treatment Centers
 Cell Based Coagulation Animation
 Rare Bleeding and Clotting Disorders Resource Room
 The Partners in Bleeding Disorders Education Program
 NHF/Novo Nordisk HANDI Library



MASAC Recommendation #166: MASAC Resolution Regarding Preferred Drug Lists

View Printer-Friendly PDF Version >>

The following resolution was approved by the Medical and Scientific Advisory Council (MASAC) of the National Hemophilia Foundation on October 29, 2005, and adopted by the NHF Board of Directors on October 30, 2005.

The Pennsylvania Department of Public Welfare (DPW) is considering the implementation of a “Preferred Drug List” (PDL) for clotting factor concentrates for hemophilia patients on Medicaid. This proposed policy of the DPW, which may designate only a few factor products as “preferred products” and which requires a strict “fail-first” prior authorization, poses grave concerns for consumers with hemophilia and other bleeding disorders. The lack of therapeutic interchangeability of products, in terms of efficacy, tolerance, and adverse drug reactions, could result in life-threatening bleeding. Moreover, limitations recommended by Medicaid on products authorized by insurers, use of mail-order pharmacies, limitations on use of specialty labs, and limits on number of outpatient visits and inpatient hospitalization days may further threaten optimal health outcomes in those with bleeding disorders. Clotting factor products are licensed by the FDA based on specific indications. Implementation of a PDL could require evidence that such a policy results in no poorer medical outcomes. Finally, the lack of equity with privately insured patients will result in substandard access to treatment in a group of patients with substantial pre-existing economic barriers to optimal health care.

For these reasons, MASAC finds a PDL to be unethical and in direct conflict with good medical care. The characteristics of each product and the resultant product choice for an individual patient require a complex decision-making process, with the ultimate product being agreed upon by the patient and his/her healthcare provider. Institution of a PDL would lead to increased costs and predictable deterioration of health in a group of patients whose health and quality of life have improved in the last decade due to the availability of a variety of safe clotting factors which work best when prescribed on an individualized basis.